New Antituberculosis Drugs: From Clinical Trial to Programmatic Use
Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensit...
Uloženo v:
| Vydáno v: | Infectious Disease Reports Ročník 8; číslo 2; s. 6569 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Italy
MDPI AG
24.06.2016
PAGEPress Publications, Pavia, Italy |
| Témata: | |
| ISSN: | 2036-7449, 2036-7430, 2036-7449 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensitive disease, highlighting the need for of new drugs. For the first time in more than 50 years, two new anti-TB drugs were approved and released. Bedaquiline is a first-in-class diarylquinoline compound that showed durable culture conversion at 24 weeks in phase IIb trials. Delamanid is the first drug of the nitroimidazole class to enter clinical practice. Similarly to bedaquiline results of phase IIb studies showed increased sputum-culture conversion at 2 months and better final treatment outcomes in patients with MDR-TB. Among repurposed drugs linezolid and carbapenems may represent a valuable drug to treat cases of MDR and extensively drugresistant TB. The recommended regimen for MDR-TB is the combination of at least four drugs to which M. tuberculosis is likely to be susceptible for the duration of 20 months. Drugs are chosen with a stepwise selection process through five groups on the basis of efficacy, safety, and cost. Clinical phase III trials on new regimen are ongoing that could prove transformative against MDR-TB, by being shorter (six months), simpler (an alloral regimen) and safer than current standard therapy. It is fundamental that the adoption of the new drugs is done responsibly to avoid inappropriate use. Concentration of inpatient MDR-TB treatment in specialized centers could be considered in countries with low numbers of cases in order to provide appropriate clinical case management and to prevent emergence of drug resistance. |
|---|---|
| AbstractList | Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensitive disease, highlighting the need for of new drugs. For the first time in more than 50 years, two new anti-TB drugs were approved and released. Bedaquiline is a first-in-class diarylquinoline compound that showed durable culture conversion at 24 weeks in phase IIb trials. Delamanid is the first drug of the nitroimidazole class to enter clinical practice. Similarly to bedaquiline results of phase IIb studies showed increased sputum-culture conversion at 2 months and better final treatment outcomes in patients with MDR-TB. Among repurposed drugs linezolid and carbapenems may represent a valuable drug to treat cases of MDR and extensively drug-resistant TB. The recommended regimen for MDR-TB is the combination of at least four drugs to which M. tuberculosis is likely to be susceptible for the duration of 20 months. Drugs are chosen with a stepwise selection process through five groups on the basis of efficacy, safety, and cost. Clinical phase III trials on new regimen are ongoing that could prove transformative against MDR-TB, by being shorter (six months), simpler (an all-oral regimen) and safer than current standard therapy. It is fundamental that the adoption of the new drugs is done responsibly to avoid inappropriate use. Concentration of in-patient MDR-TB treatment in specialized centers could be considered in countries with low numbers of cases in order to provide appropriate clinical case management and to prevent emergence of drug resistance. Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensitive disease, highlighting the need for of new drugs. For the first time in more than 50 years, two new anti-TB drugs were approved and released. Bedaquiline is a first-in-class diarylquinoline compound that showed durable culture conversion at 24 weeks in phase IIb trials. Delamanid is the first drug of the nitroimidazole class to enter clinical practice. Similarly to bedaquiline results of phase IIb studies showed increased sputum-culture conversion at 2 months and better final treatment outcomes in patients with MDR-TB. Among repurposed drugs linezolid and carbapenems may represent a valuable drug to treat cases of MDR and extensively drugresistant TB. The recommended regimen for MDR-TB is the combination of at least four drugs to which M. tuberculosis is likely to be susceptible for the duration of 20 months. Drugs are chosen with a stepwise selection process through five groups on the basis of efficacy, safety, and cost. Clinical phase III trials on new regimen are ongoing that could prove transformative against MDR-TB, by being shorter (six months), simpler (an alloral regimen) and safer than current standard therapy. It is fundamental that the adoption of the new drugs is done responsibly to avoid inappropriate use. Concentration of inpatient MDR-TB treatment in specialized centers could be considered in countries with low numbers of cases in order to provide appropriate clinical case management and to prevent emergence of drug resistance. |
| Author | MATTEELLI, Alberto Palmieri, Fabrizio CAPONE, Susanna Gualano, Gina |
| AuthorAffiliation | 2 Department of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV and TB Elimination, University of Brescia , Italy 1 Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases L. Spallanzani , Rome |
| AuthorAffiliation_xml | – name: 2 Department of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV and TB Elimination, University of Brescia , Italy – name: 1 Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases L. Spallanzani , Rome |
| Author_xml | – sequence: 1 orcidid: 0000-0001-6149-0005 fullname: Gualano, Gina – sequence: 2 fullname: CAPONE, Susanna – sequence: 3 fullname: MATTEELLI, Alberto – sequence: 4 orcidid: 0000-0001-8184-6291 fullname: Palmieri, Fabrizio |
| BackLink | https://cir.nii.ac.jp/crid/1871991017734950272$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/27403268$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kstrFTEUxoO02Fq7dCsDunAz17wmDxeFcrUPKOqiXYc8r7nMTGoyo_jfm_G2pS2Yxckh-Z2Pk5zvFdgb0-gBeIPgikKBPkaXVxgitmIdky_AIYaEtZxSufcoPwDHpWxhXUQyyslLcIA5hQQzcQjWX_3v5nSc4jQbn-3cpxJL8znPm_KpOctpaNZ9HKPVfXOdY41Tar7ntMl6GPQUbXNT_GuwH3Rf_PHdfgRuzr5cry_aq2_nl-vTq9Yy1E2tp4EzbqiQTCKosemEC04KYo1BXIdAAu1sCMgIipccCi0cpQgabwJF5Ahc7nRd0lt1m-Og8x-VdFT_DlLeKJ1rT71XDgeOONE-uEC1IwZZiLjrnGeWC6ur1slO63Y2g3fWj1PW_RPRpzdj_KE26ZeiEnNJeBX4cCeQ08_Zl0kNsVjf93r0aS4KCUgqiJms6Ltn6DbNeaxfpTAlQvCOc1Gpt487emjlflYVaHeAzamU7MMDgqBa7KCqHdRiB7XYofLkGW_jVGeWlgfF_r9V73dVY4y1YIlIcCTryBDnhMoOYo7JXzCmwrQ |
| CitedBy_id | crossref_primary_10_1016_j_ijtb_2020_09_005 crossref_primary_10_1134_S1068162023603257 crossref_primary_10_4239_wjd_v15_i5_853 crossref_primary_10_1111_jam_14478 crossref_primary_10_1016_j_ejmech_2019_02_010 crossref_primary_10_1016_j_ijtb_2017_03_006 crossref_primary_10_7759_cureus_35154 crossref_primary_10_1016_j_arbres_2019_11_015 crossref_primary_10_1016_j_molstruc_2024_138472 crossref_primary_10_1016_j_arbr_2019_11_013 crossref_primary_10_1016_j_molstruc_2025_141876 crossref_primary_10_1080_10406638_2023_2261593 crossref_primary_10_1016_j_ijtb_2019_02_009 crossref_primary_10_1080_1120009X_2022_2136447 crossref_primary_10_3201_eid2303_161916 crossref_primary_10_1128_mSphere_00606_19 crossref_primary_10_1128_AAC_00739_19 crossref_primary_10_4102_hsag_v26i0_1708 crossref_primary_10_1016_j_tube_2017_11_007 crossref_primary_10_1002_med_21602 crossref_primary_10_3390_plants9020167 crossref_primary_10_1016_j_eujim_2020_101105 crossref_primary_10_1080_17425255_2025_2525451 crossref_primary_10_12968_hmed_2018_79_6_C90 crossref_primary_10_1016_j_ijantimicag_2017_08_020 crossref_primary_10_1016_j_molstruc_2021_130941 crossref_primary_10_3390_antibiotics10080908 crossref_primary_10_1016_j_bmcl_2019_07_040 crossref_primary_10_1016_j_bcp_2017_03_017 crossref_primary_10_2106_JBJS_RVW_18_00035 crossref_primary_10_4081_idr_2016_6644 crossref_primary_10_1007_s11030_019_10004_1 crossref_primary_10_3390_jpm12040569 crossref_primary_10_1007_s12272_017_0914_1 crossref_primary_10_1007_s40475_017_0108_4 |
| Cites_doi | 10.1183/13993003.01278-2015 10.5588/ijtld.13.0075 10.1183/09031936.00188313 10.1128/AAC.42.5.1295 10.1056/NEJMoa1201964 10.1183/09031936.00159807 10.1016/S1473-3099(15)00296-0 10.1093/cid/ciu786 10.1056/NEJMoa1315817 10.4269/ajtmh.13-0004 10.1183/09031936.00125812 10.1128/AAC.00120-13 10.1016/S2213-2600(15)00063-6 10.1183/09031936.00124312 10.1016/S0140-6736(12)61080-0 10.1093/cid/ciu619 10.2165/11595340-000000000-00000 10.1186/1745-6215-13-61 10.1093/cid/civ027 10.1183/09031936.00022912 10.1128/AAC.47.9.2971-2973.2003 10.1164/rccm.201410-1801OC 10.1056/NEJMoa1112433 10.1186/1745-6215-15-353 10.1016/S0041-3879(63)80115-4 10.1056/NEJMoa0808427 10.1093/cid/cis487 10.2165/11531490-000000000-00000 10.5588/ijtld.14.0100 10.2147/IDR.S62119 10.1016/S1473-3099(10)70139-0 10.1055/s-0032-1333546 10.1056/NEJMoa1313865 10.1016/S0140-6736(14)62002-X 10.1183/09031936.00035114 10.1093/cid/ciu209 10.1128/AAC.01197-08 10.1056/NEJMoa1314210 10.1056/NEJMoa1407426 10.1183/09031936.00176314 10.1371/journal.pone.0006914 10.5588/ijtld.14.0944 10.1016/S1473-3099(09)70041-6 10.1164/rccm.201001-0077OC 10.1128/AAC.06126-11 |
| ContentType | Journal Article |
| Copyright | 2016. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright G. Gualano et al. 2016 Licensee PAGEPress, Italy |
| Copyright_xml | – notice: 2016. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright G. Gualano et al. 2016 Licensee PAGEPress, Italy |
| DBID | RYH AAYXX CITATION NPM 3V. 7X2 7X7 7XB 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA ATCPS AZQEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. M0K M0S PATMY PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PYCSY 7U8 7X8 C1K JXQ 5PM DOA |
| DOI | 10.4081/idr.2016.6569 |
| DatabaseName | CiNii Complete CrossRef PubMed ProQuest Central (Corporate) Agricultural Science Collection Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Public Health Database (Proquest) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Agricultural Science Database Health & Medical Collection (Alumni Edition) Environmental Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database (subscription) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Environmental Science Collection TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management Toxline PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection ProQuest Central (New) ProQuest Public Health ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Environmental Science Collection ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management |
| DatabaseTitleList | TOXLINE PubMed Agricultural Science Database CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 2036-7449 |
| EndPage | 6569 |
| ExternalDocumentID | oai_doaj_org_article_d2f7173aefdf4ad3b1c017d5de6c78ca PMC4927937 27403268 10_4081_idr_2016_6569 |
| Genre | Journal Article Review |
| GroupedDBID | --- 53G 5VS 67V 7X2 7X7 8C1 8FI 8FJ ABDBF ABUWG ACUHS ADBBV ADRAZ AFFHD AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS ATCPS BAEHF BAWUL BCNDV BENPR BHPHI CCPQU DIK E3Z EBD ESX F5P FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE IPNFZ KQ8 M0K M48 MODMG M~E OK1 P6G PATMY PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PYCSY RIG RPM RYH TR2 TUS UKHRP AAYXX CITATION NPM 3V. 7XB 8FE 8FH 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQQKQ PQUKI PRINS 7U8 7X8 C1K JXQ 5PM |
| ID | FETCH-LOGICAL-c615t-e4f767b4896910a2b58dfd983cbb17aff3f45cff1b8423f4508a8d4410bebf413 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 47 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000379089800003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2036-7449 2036-7430 |
| IngestDate | Mon Nov 10 04:35:54 EST 2025 Tue Nov 04 01:42:18 EST 2025 Fri Jul 11 00:25:09 EDT 2025 Tue Oct 07 07:20:13 EDT 2025 Thu Jan 02 22:29:10 EST 2025 Sat Nov 29 07:50:11 EST 2025 Tue Nov 18 21:49:00 EST 2025 Mon Nov 10 09:08:19 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Multidrug-resistant antituberculosis therapy new drugs tuberculosis |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c615t-e4f767b4896910a2b58dfd983cbb17aff3f45cff1b8423f4508a8d4410bebf413 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Conflict of interests: the authors declare no potential conflict of interests. Contributions: GG designed the content of the review and wrote the manuscript; FP, AM and SC wrote the manuscript; FP and AM critically revised the paper. |
| ORCID | 0000-0001-6149-0005 0000-0001-8184-6291 |
| OpenAccessLink | https://doaj.org/article/d2f7173aefdf4ad3b1c017d5de6c78ca |
| PMID | 27403268 |
| PQID | 2438875778 |
| PQPubID | 4770003 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d2f7173aefdf4ad3b1c017d5de6c78ca pubmedcentral_primary_oai_pubmedcentral_nih_gov_4927937 proquest_miscellaneous_1803793269 proquest_journals_2438875778 pubmed_primary_27403268 crossref_primary_10_4081_idr_2016_6569 crossref_citationtrail_10_4081_idr_2016_6569 nii_cinii_1871991017734950272 |
| PublicationCentury | 2000 |
| PublicationDate | 20160624 |
| PublicationDateYYYYMMDD | 2016-06-24 |
| PublicationDate_xml | – month: 6 year: 2016 text: 20160624 day: 24 |
| PublicationDecade | 2010 |
| PublicationPlace | Italy |
| PublicationPlace_xml | – name: Italy – name: Basel |
| PublicationTitle | Infectious Disease Reports |
| PublicationTitleAlternate | Infect Dis Rep |
| PublicationYear | 2016 |
| Publisher | MDPI AG PAGEPress Publications, Pavia, Italy |
| Publisher_xml | – name: MDPI AG – name: PAGEPress Publications, Pavia, Italy |
| References | Bastos (ref35) 2014; 59 Wells (ref9) 2015; 45 Jindani (ref24) 2014; 371 Johnston (ref30) 2009; 4 Tang (ref19) 2015; 45 Lange (ref33) 2014; 44 Dawson (ref28) 2015; 385 (ref56) 2015 Guglielmetti (ref5) 2015; 60 Daley (ref29) 2013; 34 Chang (ref49) 2013; 57 Orenstein (ref31) 2009; 9 Diacon (ref2) 2012; 56 De Lorenzo (ref20) 2013; 41 Diacon (ref27) 2012; 380 Sotgiu (ref17) 2012; 40 Rustomjee (ref23) 2008; 12 Akçakır (ref34) 2010 Krüüner (ref41) 2003; 47 (ref10) 2013 Matteelli (ref12) 2015; 15 Van Deun (ref51) 2010; 182 Mathys (ref47) 2009; 53 Nunn (ref6) 2014; 15 (ref57) 2014 Aung (ref52) 2014; 18 Velásquez (ref36) 2014; 59 Bassili (ref54) 2013; 89 Fitzpatrick (ref55) 2012; 30 (ref14) 2014 Merle (ref25) 2014; 371 Merle (ref22) 2012; 13 Diacon (ref1) 2009; 360 Rustomjee (ref13) 2015; 8 Caminero (ref45) 2010; 10 Gler (ref7) 2012; 366 (ref11) 2014 Piubello (ref53) 2014; 18 Gillespie (ref26) 2014; 371 Zumla (ref48) 2015; 3 (ref50) 2008 Tiberi (ref21) 2016; 47 Stahlmann (ref44) 2010; 27 (ref37) 2008 Katiyar (ref39) 2008; 12 Angel (ref46) 1963; 44 Skripconoka (ref8) 2013; 41 Migliori (ref42) 2008; 31 (ref58) 2015 Diacon (ref16) 2015; 191 Ziganshina (ref43) 2008; 1 Tang (ref15) 2015; 60 Alangaden (ref40) 1998; 42 Diacon (ref3) 2014; 371 Dooley (ref38) 2012; 55 Ndjeka (ref4) 2015; 19 (ref32) 2014 Lee (ref18) 2012; 367 25795076 - Lancet. 2015 May 2;385(9979):1738-47 22070215 - Pharmacoeconomics. 2012 Jan;30(1):63-80 20797644 - Lancet Infect Dis. 2010 Sep;10(9):621-9 25234807 - Eur Respir J. 2015 Jan;45(1):161-70 19246019 - Lancet Infect Dis. 2009 Mar;9(3):153-61 25199531 - Trials. 2014 Sep 09;15:353 22670901 - N Engl J Med. 2012 Jun 7;366(23):2151-60 14013125 - Tubercle. 1963 Jun;44:215-24 18230245 - Int J Tuberc Lung Dis. 2008 Feb;12(2):139-45 25622149 - Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53 23926140 - Am J Trop Med Hyg. 2013 Aug;89(2):271-80 25320286 - Clin Infect Dis. 2015 Jan 15;60(2):188-94 25337748 - N Engl J Med. 2014 Oct 23;371(17):1588-98 22997218 - Eur Respir J. 2013 Jun;41(6):1386-92 18378786 - Eur Respir J. 2008 Apr;31(4):904-5 12937004 - Antimicrob Agents Chemother. 2003 Sep;47(9):2971-3 20442432 - Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92 20210367 - Drugs Aging. 2010 Mar 1;27(3):193-209 23075177 - N Engl J Med. 2012 Oct 18;367(16):1508-18 25773212 - Lancet Respir Med. 2015 Mar;3(3):220-34 19742330 - PLoS One. 2009 Sep 09;4(9):e6914 25097082 - Clin Infect Dis. 2014 Nov 15;59(10):1364-74 24729493 - Clin Infect Dis. 2014 Jul 1;59(1):9-15 18230244 - Int J Tuberc Lung Dis. 2008 Feb;12(2):128-38 22828481 - Lancet. 2012 Sep 15;380(9846):986-93 23018916 - Eur Respir J. 2013 Jun;41(6):1393-400 26585427 - Eur Respir J. 2016 Jan;47(1):333-6 25605283 - Clin Infect Dis. 2015 May 1;60(9):1361-7 25700385 - Eur Respir J. 2015 May;45(5):1498-501 22607233 - Trials. 2012 May 18;13:61 26604805 - Infect Drug Resist. 2015 Oct 29;8:359-66 26162365 - Int J Tuberc Lung Dis. 2015 Aug;19(8):979-85 22615332 - Clin Infect Dis. 2012 Aug;55(4):572-81 25196020 - N Engl J Med. 2014 Oct 23;371(17):1577-87 26461941 - Lancet Infect Dis. 2015 Oct;15(10):1131-2 25216832 - Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94 23460005 - Semin Respir Crit Care Med. 2013 Feb;34(1):44-59 9593173 - Antimicrob Agents Chemother. 1998 May;42(5):1295-7 22391540 - Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6 22496332 - Eur Respir J. 2012 Dec;40(6):1430-42 19237648 - Antimicrob Agents Chemother. 2009 May;53(5):2100-9 24659544 - Eur Respir J. 2014 Jul;44(1):23-63 25140958 - N Engl J Med. 2014 Aug 21;371(8):723-32 18254061 - Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004795 19494215 - N Engl J Med. 2009 Jun 4;360(23):2397-405 25216831 - Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7 23774431 - Antimicrob Agents Chemother. 2013 Sep;57(9):4097-104 25337749 - N Engl J Med. 2014 Oct 23;371(17):1599-608 |
| References_xml | – year: 2008 ident: ref50 – volume: 47 start-page: 333 year: 2016 ident: ref21 article-title: Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience publication-title: Eur Respir J doi: 10.1183/13993003.01278-2015 – year: 2010 ident: ref34 article-title: Correlates of treatment outcomes of multidrug-resistant tuberculosis (MDR-TB): a systematic review and meta-analysis publication-title: Thesis Dissertation. Montreal, Canada, McGill University Department of Epidemiology, Statistics and Occupational Health – volume: 18 start-page: 1188 year: 2014 ident: ref53 article-title: High cure rate for standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.13.0075 – volume: 44 start-page: 23 year: 2014 ident: ref33 article-title: Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement publication-title: Eur Respir J doi: 10.1183/09031936.00188313 – volume: 42 start-page: 1295 year: 1998 ident: ref40 article-title: Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.42.5.1295 – volume: 367 start-page: 1508 year: 2012 ident: ref18 article-title: Linezolid for treatment of chronic extensively drug-resistant tuberculosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1201964 – volume: 31 start-page: 904 year: 2008 ident: ref42 article-title: Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? publication-title: Eur Respir J doi: 10.1183/09031936.00159807 – volume: 15 start-page: 1131 year: 2015 ident: ref12 article-title: Compassionate and optimum use of new tuberculosis drugs publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)00296-0 – volume: 60 start-page: 188 year: 2015 ident: ref5 article-title: MDR-TB Management group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort publication-title: Clin Infect Dis doi: 10.1093/cid/ciu786 – year: 2014 ident: ref57 – volume: 371 start-page: 1588 year: 2014 ident: ref25 article-title: A four-month gatifloxacin-containingregimen for treating tuberculosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1315817 – volume: 89 start-page: 271 year: 2013 ident: ref54 article-title: Review article: a systematic review of the effectiveness of hospital and ambulatory-based management of multidrug-resistant tuberculosis publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.13-0004 – volume: 41 start-page: 2393 year: 2013 ident: ref8 article-title: Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis publication-title: Eur Respir J doi: 10.1183/09031936.00125812 – year: 2014 ident: ref14 article-title: Policy implementation package for new TB drug introduction – year: 2014 ident: ref11 – volume: 57 start-page: 4097 year: 2013 ident: ref49 article-title: WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00120-13 – year: 2014 ident: ref32 – volume: 3 start-page: 220 year: 2015 ident: ref48 article-title: Tuberculosis treatment and managementan update on treatment regimens, trials, new drugs, and adjunct therapies publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(15)00063-6 – volume: 41 start-page: 1386 year: 2013 ident: ref20 article-title: Efficacy and safety of meropenem/clavulanate added to linezolid containing regimens in the treatment of M/XDR-TB publication-title: Eur Respir J doi: 10.1183/09031936.00124312 – volume: 380 start-page: 986 year: 2012 ident: ref27 article-title: 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomized trial publication-title: Lancet doi: 10.1016/S0140-6736(12)61080-0 – volume: 59 start-page: 1364 year: 2014 ident: ref35 article-title: Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis publication-title: Clin Infect Dis doi: 10.1093/cid/ciu619 – volume: 30 start-page: 63 year: 2012 ident: ref55 article-title: A systematic review of the costant cost effectiveness of treatment for multidrug-resistant-tuberculosis publication-title: Pharmacoeconomics doi: 10.2165/11595340-000000000-00000 – volume: 13 start-page: 61 year: 2012 ident: ref22 article-title: A pivotal registrationphase III, multicenter, randomized tuberculosis controlled trial:design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project publication-title: Trials doi: 10.1186/1745-6215-13-61 – volume: 60 start-page: 1361 year: 2015 ident: ref15 article-title: Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China publication-title: Clin Infect Dis doi: 10.1093/cid/civ027 – volume: 40 start-page: 1430 year: 2012 ident: ref17 article-title: Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis publication-title: Eur Respir J doi: 10.1183/09031936.00022912 – year: 2008 ident: ref37 – volume: 47 start-page: 2971 year: 2003 ident: ref41 article-title: Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacteriumtuberculosis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.47.9.2971-2973.2003 – volume: 191 start-page: 943 year: 2015 ident: ref16 article-title: Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201410-1801OC – volume: 12 start-page: 129 year: 2008 ident: ref39 article-title: A randomized controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 366 start-page: 2151 year: 2012 ident: ref7 article-title: Delamanid for multidrugresistant pulmonary tuberculosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1112433 – year: 2015 ident: ref58 – year: 2013 ident: ref10 – volume: 15 start-page: 353 year: 2014 ident: ref6 article-title: Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial publication-title: Trials doi: 10.1186/1745-6215-15-353 – volume: 44 start-page: 215 year: 1963 ident: ref46 article-title: A controlled comparison of cycloserine plus ethionamide with cycloserine plus thiacetazone in patientswith active pulmonary tuberculosis despite prolonged previous chemotherapy publication-title: Tubercle doi: 10.1016/S0041-3879(63)80115-4 – volume: 360 start-page: 2397 year: 2009 ident: ref1 article-title: The diarylquinoline TMC207 for multidrug-resistant tuberculosis publication-title: N Engl J Med doi: 10.1056/NEJMoa0808427 – volume: 55 start-page: 572 year: 2012 ident: ref38 article-title: Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis publication-title: Clin Infect Dis doi: 10.1093/cid/cis487 – volume: 27 start-page: 193 year: 2010 ident: ref44 article-title: Safety considerations of fluoroquinolones in the elderly publication-title: Drugs Aging doi: 10.2165/11531490-000000000-00000 – volume: 18 start-page: 1180 year: 2014 ident: ref52 article-title: Successful 9-month Bangladesh regimen for multidrug-resistant tuberculosisamong over 500 consecutive patients publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.14.0100 – volume: 8 start-page: 359 year: 2015 ident: ref13 article-title: Delamanid expanded access novel treatment of drug resistant tuberculosis publication-title: Infect Drug Resist doi: 10.2147/IDR.S62119 – volume: 12 start-page: 128 year: 2008 ident: ref23 article-title: A Phase II study of thesterilising activities of ofloxacin, gatifloxacin and moxifloxacin inpulmonary tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 1 start-page: CD004795 year: 2008 ident: ref43 article-title: Fluoroquinolones for treating tuberculosis publication-title: Cochrane Database Syst Rev – volume: 10 start-page: 621 year: 2010 ident: ref45 article-title: Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(10)70139-0 – volume: 34 start-page: 44 year: 2013 ident: ref29 article-title: Management of multidrug resistant tuberculosis publication-title: Semin Respir Crit Care Med doi: 10.1055/s-0032-1333546 – volume: 371 start-page: 723 year: 2014 ident: ref3 article-title: Multidrug-resistant tuberculosis and culture conversion with bedaquiline publication-title: N Engl J Med doi: 10.1056/NEJMoa1313865 – year: 2015 ident: ref56 – volume: 385 start-page: 1738 year: 2015 ident: ref28 article-title: Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b,open-label, partly randomized trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis publication-title: Lancet doi: 10.1016/S0140-6736(14)62002-X – volume: 45 start-page: 161 year: 2015 ident: ref19 article-title: Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China publication-title: Eur Respir J doi: 10.1183/09031936.00035114 – volume: 59 start-page: 9 year: 2014 ident: ref36 article-title: Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death publication-title: Clin Infect Dis doi: 10.1093/cid/ciu209 – volume: 53 start-page: 2100 year: 2009 ident: ref47 article-title: Molecular genetics of paraaminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacteriumtuberculosis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01197-08 – volume: 371 start-page: 1599 year: 2014 ident: ref24 article-title: High-dose rifapentine with moxifloxacin for pulmonary tuberculosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1314210 – volume: 371 start-page: 1577 year: 2014 ident: ref26 article-title: Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1407426 – volume: 45 start-page: 1498 year: 2015 ident: ref9 article-title: Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid publication-title: Eur Respir J doi: 10.1183/09031936.00176314 – volume: 4 start-page: e6914 year: 2009 ident: ref30 article-title: Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis publication-title: PLoS One doi: 10.1371/journal.pone.0006914 – volume: 19 start-page: 979 year: 2015 ident: ref4 article-title: Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.14.0944 – volume: 9 start-page: 153 year: 2009 ident: ref31 article-title: Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis publication-title: Lancet doi: 10.1016/S1473-3099(09)70041-6 – volume: 182 start-page: 684 year: 2010 ident: ref51 article-title: Short, highly effective and inexpensive standardized treatment of multi-drug-resistant tuberculosis publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201001-0077OC – volume: 56 start-page: 3271 year: 2012 ident: ref2 article-title: Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.06126-11 – reference: 25773212 - Lancet Respir Med. 2015 Mar;3(3):220-34 – reference: 25234807 - Eur Respir J. 2015 Jan;45(1):161-70 – reference: 22828481 - Lancet. 2012 Sep 15;380(9846):986-93 – reference: 19742330 - PLoS One. 2009 Sep 09;4(9):e6914 – reference: 25199531 - Trials. 2014 Sep 09;15:353 – reference: 25196020 - N Engl J Med. 2014 Oct 23;371(17):1577-87 – reference: 25140958 - N Engl J Med. 2014 Aug 21;371(8):723-32 – reference: 18378786 - Eur Respir J. 2008 Apr;31(4):904-5 – reference: 25622149 - Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53 – reference: 22070215 - Pharmacoeconomics. 2012 Jan;30(1):63-80 – reference: 23926140 - Am J Trop Med Hyg. 2013 Aug;89(2):271-80 – reference: 26604805 - Infect Drug Resist. 2015 Oct 29;8:359-66 – reference: 22391540 - Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6 – reference: 19246019 - Lancet Infect Dis. 2009 Mar;9(3):153-61 – reference: 18230245 - Int J Tuberc Lung Dis. 2008 Feb;12(2):139-45 – reference: 25337748 - N Engl J Med. 2014 Oct 23;371(17):1588-98 – reference: 23460005 - Semin Respir Crit Care Med. 2013 Feb;34(1):44-59 – reference: 22496332 - Eur Respir J. 2012 Dec;40(6):1430-42 – reference: 20442432 - Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92 – reference: 18230244 - Int J Tuberc Lung Dis. 2008 Feb;12(2):128-38 – reference: 25700385 - Eur Respir J. 2015 May;45(5):1498-501 – reference: 25605283 - Clin Infect Dis. 2015 May 1;60(9):1361-7 – reference: 24729493 - Clin Infect Dis. 2014 Jul 1;59(1):9-15 – reference: 22670901 - N Engl J Med. 2012 Jun 7;366(23):2151-60 – reference: 23075177 - N Engl J Med. 2012 Oct 18;367(16):1508-18 – reference: 23774431 - Antimicrob Agents Chemother. 2013 Sep;57(9):4097-104 – reference: 20210367 - Drugs Aging. 2010 Mar 1;27(3):193-209 – reference: 25337749 - N Engl J Med. 2014 Oct 23;371(17):1599-608 – reference: 23018916 - Eur Respir J. 2013 Jun;41(6):1393-400 – reference: 14013125 - Tubercle. 1963 Jun;44:215-24 – reference: 24659544 - Eur Respir J. 2014 Jul;44(1):23-63 – reference: 9593173 - Antimicrob Agents Chemother. 1998 May;42(5):1295-7 – reference: 19237648 - Antimicrob Agents Chemother. 2009 May;53(5):2100-9 – reference: 25320286 - Clin Infect Dis. 2015 Jan 15;60(2):188-94 – reference: 26461941 - Lancet Infect Dis. 2015 Oct;15(10):1131-2 – reference: 18254061 - Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004795 – reference: 22607233 - Trials. 2012 May 18;13:61 – reference: 22997218 - Eur Respir J. 2013 Jun;41(6):1386-92 – reference: 20797644 - Lancet Infect Dis. 2010 Sep;10(9):621-9 – reference: 22615332 - Clin Infect Dis. 2012 Aug;55(4):572-81 – reference: 26585427 - Eur Respir J. 2016 Jan;47(1):333-6 – reference: 25216832 - Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94 – reference: 25795076 - Lancet. 2015 May 2;385(9979):1738-47 – reference: 26162365 - Int J Tuberc Lung Dis. 2015 Aug;19(8):979-85 – reference: 19494215 - N Engl J Med. 2009 Jun 4;360(23):2397-405 – reference: 25097082 - Clin Infect Dis. 2014 Nov 15;59(10):1364-74 – reference: 25216831 - Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7 – reference: 12937004 - Antimicrob Agents Chemother. 2003 Sep;47(9):2971-3 |
| SSID | ssj0000396473 |
| Score | 2.268984 |
| SecondaryResourceType | review_article |
| Snippet | Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than... |
| SourceID | doaj pubmedcentral proquest pubmed crossref nii |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 6569 |
| SubjectTerms | antituberculosis therapy Carbapenems Clinical outcomes Clinical trials Conversion Drug resistance Drugs Health services Linezolid Multidrug resistance Multidrug resistant organisms Multidrug-resistant Multidrug-resistant; antituberculosis therapy; new drugs; tuberculosis new drugs Nitroimidazole Other systems of medicine Review RZ201-999 Sputum Tuberculosis |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection (Proquest) dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Ni9UwEA-6ehDE74_qrkQQT9ZNk7RJvYguLp4WDwrvVvK5FpZ2bV_9-51p86pP1IuXUpq0JJ2ZzCQz8xtCXuii4t4LnjvHylwCB-cI850rXgbto49BmLnYhDo705tN_SkduI0prHK3Js4Lte8dnpEfcyk0gq8r_fbyW45Vo9C7mkpoXCXXsGw28rnaqPWMhQnMs0QnM7rbclCWbIHZlKAIj1uPeKBF9RpMmnpPLc3o_aBsurb9k-H5e_zkLwrp9Pb_TuUOuZVMUfpu4Z275Ero7pGbyzkeXdKT7pMTWAWpwVzeyYbBTRf92I7UD9P5-IZibgrd5VbSuQAI3fY0xXzNYLB0GsMD8uX0w-eTj3kqvJA7MHC2eZBRVcpKXVdgTRhuSyRbrYWztlAmRhFl6WIsrAZrDO6ZNtqDYcVssBHU4kNy0PVdeExoWUZm6tqC5RNkYMEAIWLlrUJ_rI91Rl7t_nvjEio5Fse4aGB3gmQC4RwaJFODZMrIy7X75QLH8beO75GIaydE0Z4f9MN5k4Sy8TxiEIIJwJPSeGELBwuUL32onNLOZOQIWADGhVfgLwwTgw5KwK4StvM8I4c7AjdJ9MfmJ3Uz8nxtBqFFT4zpQj-N8C0mFFrOMM5HCy-tI-VKMmiBt9Uel-1NZb-la7_OwOCy5gh3-OTfw3pKbuBvwng3Lg_JwXaYwhG57r5v23F4NkvQD7kvIoQ priority: 102 providerName: ProQuest |
| Title | New Antituberculosis Drugs: From Clinical Trial to Programmatic Use |
| URI | https://cir.nii.ac.jp/crid/1871991017734950272 https://www.ncbi.nlm.nih.gov/pubmed/27403268 https://www.proquest.com/docview/2438875778 https://www.proquest.com/docview/1803793269 https://pubmed.ncbi.nlm.nih.gov/PMC4927937 https://doaj.org/article/d2f7173aefdf4ad3b1c017d5de6c78ca |
| Volume | 8 |
| WOSCitedRecordID | wos000379089800003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: M~E dateStart: 20090101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Agricultural Science Database customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: M0K dateStart: 20090901 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: PATMY dateStart: 20090901 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: 7X7 dateStart: 20090901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: BENPR dateStart: 20090901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (Proquest) customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: 8C1 dateStart: 20090901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: PIMPY dateStart: 20090901 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA96-iCI-G31bokgPlkvbdMm9c1b7lBklyIK61PJ51k4uke7vb_fmbS77Iriiy_D0qQlnUw6v9nJ_ELIG5kUqbVZGhvD8piDBcdI8x2LNHfSeutdpsJhE2K5lKtVWe0d9YV7wkZ64FFxpzb1mChWDu7jymY6MWBENreuMEKaAI2YKPeCqfANzrDCEtPLmGiLwU2ykWCTgws8bSwygSbFewAz5YFDCrz94GbapvkT5Px95-SeK7p4SB5MGJJ-HMf-iNxy7WNyf_wDjo51RU_IHD5fVGER7qBdZ4ardd_01HbDZf-BYlEJ3RZF0nByB92s6bRZK7C40qF3T8n3i_Nv80_xdGJCbACZbGLHvSiE5rIsAAaoVOeo71JmRutEKO8zz3PjfaIlwCj4zaSSFhAR00578GfPyFG7bt0LQvPcM1WWGiCL4445BXr0hdUCE6nWlxF5t1VbbSY6cTzV4qqGsAK1DKuqq1HLNWo5Im933a9HHo2_dTzDOdh1QvrrcAGMop6Mov6XUUTkBGYQxoUygZgQUDB0EBmEgxCHpxE53s5tPa3Zvk55JpHeX8iIvN41w2rDFIpq3Xro4VksEwh5YZzPR1PYjRTiewYtcLc4MJKDVzlsaZufgdGblynyFL78H-_-itxDZeJ2tpQfk6NNN7gTctfcbJq-m5HbYiWClCDlPJmRO2fny-rrLCwgkAv2BeSyWkBL9XlR_fgFIekeHQ |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLbKFAkkxL4EWjAScCI0cZzYQUIIClVHbUdzKFJ7Co6XEqlKSjIB8af4jbyXZWAQcOuBSzSKPdFL_PktfhshT2SYMGMi5msdxD4HBPtY5tsXLLbSOONspLpmE2I2k0dH6XyNfB9zYTCscuSJHaM2lcYz8i3GI4nF14V8ffbZx65R6F0dW2j0sNiz376Cyda8mr6D9X3K2M77w-1df-gq4GuQ3gvfcicSkXOZJiAqFctjpCmVkc7zUCjnIsdj7VyYS1A14HcglTSgNQS5zR3wfHjuBbLOEewTsj6fHsyPl6c6QYSZnejWRgefD-I56At7chC9W4XBCqRh8gKUqHRFEHb9AkC8lUXxJ1X394jNX0TgzrX_7eNdJ1cHZZu-6XfHDbJmy5vkSn9SSfsErFtkG_g8VZit3Oa21u1p1RQNNXV70rykmH1Dx-xR2rU4oYuKDlFtXblb2jb2NvlwLu9xh0zKqrT3CI1jF6g0zUG3s9wGVsHCu8TkAj3OxqUeeT6uc6aHuuvY_uM0A_sLYQHsp84QFhnCwiPPltPP-oIjf5v4FkGznIR1wrsbVX2SDWwnM8xhmIWysOu4MlEeamDBJjY20UJq5ZFNgBzQhdcQjGcwF2CCiMBuDphgHtkYAZUNzK3JfqLJI4-Xw8CW0NekSlu1DTwriATaBkDn3R67S0qZ4AGMwL_FCqpXXmV1pCw-daXPecqwoOP9f5P1iFzaPTzYz_ans70H5DJ-MozuY3yDTBZ1azfJRf1lUTT1w2H_UvLxvFH_AyC5gfY |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwELaWLkJIiPcjsAtGAk6EJo4TO0gIwS4V1ULVA0jLKcSvJdIqWZIGxF_j1zGTR6EIuO2BS1XVbjRJPs_DnvmGkAcyTJgxEfO1DmKfA4J9pPn2BYutNM44G-VdswmxWMjDw3S5Rb6PtTCYVjnqxE5Rm0rjHvmU8Ugi-bqQUzekRSz3Z89PPvvYQQpPWsd2Gj1EDuy3rxC-Nc_m-_CuHzI2e_Vu77U_dBjwNVjylW-5E4lQXKYJmM2cqRjlS2WklQpF7lzkeKydC5UEtwO-BzKXBjyIQFnlQP_Ddc-QbXDJOZuQ7eX87fLDeocniLDKE4-48bDPB1Md9CSfHMzwtDDIRhomT8ChSjeMYtc7AExdWRR_cnt_z978xRzOLv3PD_IyuTg44fRFv2qukC1bXiUX-h1M2hdmXSN7oP9pjlXMrbK1bo-rpmioqduj5inFqhw6VpXSrvUJXVV0yHbraHBp29jr5P2p3McNMimr0t4iNI5dkKepAp_PchvYHEDgEqMEnkQbl3rk8fjOMz3wsWNbkOMM4jKECKilOkOIZAgRjzxaTz_piUj-NvElAmg9CfnDux-q-igb1FFmmMP0i9zCauS5iVSoQTWb2NhEC6lzj-wC_EAu_AwhqIYwAiaICOLpgAnmkZ0RXNmg9JrsJ7I8cn89DOoKz6Dy0lZtA9cKIoExA8h5s8fxWlImeAAj8G-xgfCNW9kcKYtPHSU6TxkSPd7-t1j3yDmAevZmvji4Q87jE8OkP8Z3yGRVt3aXnNVfVkVT3x2WMiUfTxv0PwDyuIq2 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+Antituberculosis+Drugs%3A+From+Clinical+Trial+to+Programmatic+Use&rft.jtitle=Infectious+disease+reports&rft.au=Gualano%2C+Gina&rft.au=Capone%2C+Susanna&rft.au=Matteelli%2C+Alberto&rft.au=Palmieri%2C+Fabrizio&rft.date=2016-06-24&rft.pub=PAGEPress+Publications%2C+Pavia%2C+Italy&rft.issn=2036-7430&rft.eissn=2036-7449&rft.volume=8&rft.issue=2&rft_id=info:doi/10.4081%2Fidr.2016.6569&rft_id=info%3Apmid%2F27403268&rft.externalDocID=PMC4927937 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2036-7449&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2036-7449&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2036-7449&client=summon |